Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canopus BioPharma has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis.
Subscribe to our email newsletter
This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent, the company said.
Oral and gastrointestinal mucositis is a painful, debilitating, and sometimes fatal, side effect of radiation therapy and cancer chemotherapy.